|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 239,500.00 KRW | +5.27% |
|
+11.66% | +32.32% |
| 02-05 | CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5) | RE |
| 01-30 | Celltrion Launches Autoimmune Drug Aptozma in Europe | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 36.18B | |||||
| 46.14B | |||||
| 38.87B | |||||
| 30.05B | |||||
| 18.94B | - | - | - | - | - |
| 13.55B |
- Stock Market
- Equities
- A068270 Stock
- Charts Celltrion, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition